TITLE

Psicoterapia frente a farmacoterapia en depresión en atención ambulatoria

AUTHOR(S)
Güemes, I.; Guillen, V.; Ballesteros, J.
PUB. DATE
September 2008
SOURCE
Actas Espanolas de Psiquiatria;sep2008, Vol. 36 Issue 5, p79
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Depression in Europe has a prevalence rate of 3,9%. One of the main work loads in out-patient care comes from treatment of affective disorders. The objective of the present study is to compare the efficacy of psychotherapy versus drug therapy in the treatment of affective disorders. The systematic review carried out has found 6 randomized controlled trials with a pill-placebo control group. The conclusions obtained after re-analyzing each study point out to comparatively equal efficacy of the active treatments and placebo in mild depressions. On the other hand, no significant differences were observed in relationship to the psychotherapeutic treatment efficacy versus drug treatments in moderate and severe depressions, these out-performing placebo efficacy.
ACCESSION #
35061252

 

Related Articles

  • Psychotherapy Versus Pharmacotherapy of Depression: What's the Evidence? Leichsenring, Falk; Steinert, Christiane; Hoyer, Jürgen // Zeitschrift für Psychosomatische Medizin und Psychotherapie;Jun2016, Vol. 62 Issue 2, p190 

    Objectives: Depression may be treated by psychotherapy or pharmacotherapy or their combination. There is an ongoing debate whether one of these approaches is possibly superior. A recent meta-analysis reported results in favour of pharmacotherapy. Methods: Individual studies and meta-analyses on...

  • St. John's Wort. Lawvere, Silvana; Mahoney, Martin C. // American Family Physician;12/1/2005, Vol. 72 Issue 11, p2249 

    St. John's wort has been used to treat a variety of conditions. Several brands are standardized for content of hypericin and hyperforin, which are among the most researched active components of St. John's wort. St. John's wort has been found to be superior to placebo and equivalent to standard...

  • Continuation therapy with amitriptyline in depression. Coppen, A.; Ghose, K.; Montgomery, S.; Rama Rao, V. A.; Bailey, J.; Jorgensen, A. // British Journal of Psychiatry;Jul78, Vol. 133, p28 

    Thirty-two patients who had responded to amitriptyline (150 mg daily) when suffering from a depressive illness were allocated either to receive placebo or to remain on the same medication for one year. Plasma concentrations of the drug were regularly estimated. There was no correlation between...

  • Depression: Psychologic and Pharmacologic Therapy. Miller, Karl E. // American Family Physician;4/1/2005, Vol. 71 Issue 7, p1426 

    Discusses research being done on the use in the treatment of patients with depression. Reference to a study by S. Pampallona et al, published in the July 2004 issue of the journal "Archives of General Psychiatry"; Procedures for the study; Effectiveness of the combination of pharmacotherapy and...

  • Review: bright light therapy and dawn simulation reduce symptom severity in seasonal affective disorder. Golden, R. N.; Gaynes, B. N.; Ekstrom, R. D.; Simon, Gregory // Evidence Based Medicine;Oct2005, Vol. 10 Issue 5, p146 

    The article discusses whether light therapy is efficacious for treatment of mood disorders. English language randomized controlled trials of adults 18-65 years of age who had a diagnosis of mood disorder were in the acute phase of treatment. Bright light therapy reduces the severity of...

  • What is the State of the Evidence? Thase, Michael E. // Psychiatric Annals;Dec2003, Vol. 33 Issue 12, p813 

    Discusses therapeutic alternatives for difficult-to-treat depression. Treatment algorithms and practice guidelines; Definitions of treatment resistance; Antidepressant combinations that may be utilized.

  • Levomilnacipran for the treatment of major depressive disorder: a review. Asnis, Gregory M.; Henderson, Margaret A. // Neuropsychiatric Disease & Treatment;2015, Vol. 11, p125 

    Levomilnacipran (LVM, Fetzima®) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including...

  • EL EFECTO PLACEBO EN LOS ENSAYOS CLÍNICOS CON ANTIDEPRESIVOS. Silva Ibarra, Hernán // Acta Bioéthica;2009, Vol. 15 Issue 2, p172 

    Recent studies determined that antidepressives of new generation were inadequate for moderate or severe depressions. The improvement these diseases show with medication or with a placebo isn't very different, according to statistics. Antidepressives seem to be efficient only upon patients that...

  • Treating depression in children and adolescents: what options now? Varley, Christopher K. // CNS Drugs;2006, Vol. 20 Issue 1, p1 

    There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics